期刊文献+

抗KDR3单克隆抗体的制备和生物活性的鉴定 被引量:1

Generation and Characterization of Monoclonal Antibodies Against Domain 3 of VEGF Receptor II
下载PDF
导出
摘要 目的:制备抗KDR3单克隆抗体,研究其阻断VEGF受体的作用。方法:将抗KDR3单克隆抗体腹水,采用ELISA酶免疫分析方法,测定其效价,提取ECV304细胞膜蛋白用Westernblot方法进行识别抗原的鉴定,并测定抗KDR3单克隆抗体的活性。结果:获得一株稳定分泌抗KDR3的杂交瘤细胞株,所产生抗体可阻断VEGF对人脐静脉内皮细胞系ECV304的刺激增生作用。结论:抗KDR中和抗体IMC-ICI和抗KDR3单克隆抗体同样对ECV304细胞都表现出对外源性VEGF有明显抑制作用,而且对内源性VEGF也有明显抑制作用。抗KDR3单克隆抗体在肿瘤治疗的过程中将起一定的作用。 Objective:To prepare the monoclonal antibody directing against KDR3of VEGF receptor II and to study its biological activity.Methods:The ascitic fluid was purified by protein G,and its titer was assayed by ELASA.The memberane of ECV304was prepared to de-tected the binding activity of the monoclonal antibody.Results:A monoclonal antibody was ob-tained,which could inhibit proliferation of ECV304induced by VEGF.Conclusion:The antibody directing against KDR3inhibited proliferation of ECV304by blocking VEGF binding to KDR and could be potent in the treatment of tumor.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2003年第11期812-815,共4页 Chinese Journal of Clinical Oncology
基金 国家攀登计划项目(95-专-10) 天津市重大科技攻关项目基金资助(编号:003119511)
关键词 VEGF VEGF受体 抗KDR3抗体 VEGF VEGF receptor KDR3antibady
  • 相关文献

参考文献2

二级参考文献4

共引文献7

同被引文献10

  • 1Pugh C, Ratcliffe P. Regulation of angiogenesis by hypoxia: Role of the HIF system[J]. Nature Med, 2003, 9(6) : 677 -684.
  • 2Terman B, Khandke L, Dougher Vermazan M, et al. VEGF receptor subtypes KDR and Flt-1 show different sensitivities to heparin and placenta growth factor[J]. Gowth Factor, 1994, 11 (8) : 187 -195.
  • 3Shalaby F, Gertsenstein M, Rossant J, et al. Failue of blood-island formation and vasculogenesis in Flk-1 deficient mice [ J]. Nature, 1995, 376(6) : 62 -66.
  • 4Kamba T. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature[ J]. Am J Physiol Heart Circ Physiol, 2006, 290(2) : H560 -576.
  • 5Folkman J. Tumor angiogenesis: Theraputic implication [ J ]. N Engl J Med, 1971, 285(21 ) :1182 - 1186.
  • 6Witte L, Zhu Z. Inhibition of tumor growth and metastasis by targeting tumor associated antiogenesis with antagonists to the receptors of vascular endothelial growth factor[ J ]. Invest New Drugs, 1999, 17 ( 3 ) : 195 -212.
  • 7Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer [ J ]. Nat Rev Drug Discov, 2004, 3(5) : 391 -400.
  • 8Miao H, Hu K, Jimenea X, et al. Potent neutralization of VEGF biological activities with a fully human antibosy Fab fragment directed against VEGF receptor 2 [ J ]. Biochem Biophys Res Commun, 2006, 345 ( 1 ) : 438 - 445.
  • 9Matsumoto T, Bohaman S, Dixelius J, et al. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis[J]. EMBO J, 2005, 24( 13): 2342-2353.
  • 10Sakurai Y, Ohgimoto K, Kataoka Y, et al. Essential role of Flk-1 ( VEGF receptor 2 ) tyrosine residue 1173 in vasculogenesis in vascu- logenesis in mice [ J ]. Proc Natl Acad Sci USA, 2005, 102 ( 4 ) : 1076 - 1081.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部